Financial Gravity Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Financial Gravity Asset Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.02K	Hold	100	–	–	﹤0.01%	669
2025 Q4	$2.51K	Hold	100	–	–	﹤0.01%	589
2025 Q3	$2.26K	Buy	+100	New	+$2.33K	﹤0.01%	758
2025 Q1	$2.19K	Buy	+100	New	+$2.76K	﹤0.01%	806
2024 Q2	$3.84K	Sell	100 -1	-1%	-$45	﹤0.01%	644
2024 Q1	$6.07K	Buy	101 +1	+1%	+$64	﹤0.01%	548
2023 Q4	$5.99K	Buy	+100	New	+$5.07K	﹤0.01%	564

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Financial Gravity Asset Management's APLS Position: Q1 2026 in Review

Financial Gravity Asset Management held its Apellis Pharmaceuticals (APLS) position steady in Q1 2026 at 100 shares worth $4.02K. The position accounts for ﹤0.01% of the portfolio, ranked #669.

Financial Gravity Asset Management first reported a position in APLS in Q4 2023 and has held it in 7 quarters since. The position peaked at $6.07K in Q1 2024. 324 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

Financial Gravity Asset Management held 100 shares of Apellis Pharmaceuticals worth $4.02K as of Q1 2026.
Financial Gravity Asset Management left its Apellis Pharmaceuticals share count unchanged in Q1 2026.
Apellis Pharmaceuticals made up ﹤0.01% of Financial Gravity Asset Management's portfolio in Q1 2026, its #669 holding.
Financial Gravity Asset Management first reported a position in Apellis Pharmaceuticals in Q4 2023 and has held it in 7 quarters since.
Financial Gravity Asset Management's Apellis Pharmaceuticals position peaked at $6.07K in Q1 2024.
324 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Financial Gravity Asset Management's 13F filing for Q1 2026, filed 8 May 2026.